Nevra Alkanlı

Dr. Nevra Alkanlı

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SASuleyman Serdar Alkanli
Suleyman Serdar Alkanli
NANevra Alkanlı
Nevra Alkanlı
AAARZU AY
ARZU AY
IAIsil Albeniz
Isil Albeniz


8 September 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
AAARZU AY
ARZU AY
TGTevfik Gulyasar
Tevfik Gulyasar
NANevra Alkanlı
Nevra Alkanlı
TSTammam Sipahi
Tammam Sipahi
İÇİrfan Çiçin
İrfan Çiçin
NSNecdet Sut
Necdet Sut

8 April 2020
Verified
Book Chapter
Open access
PDF file
NANevra Alkanlı
Nevra Alkanlı
AAARZU AY
ARZU AY
Parkinson’s disease (PD) is a neurodegenerative disorder affecting the motor system and occurring in the central nervous system. One of the symptoms of PD is accumulation of Lewy bodies and Lewy neurites. The alpha-synuclein (SNCA) gene is part of the protein complex called Lewy body. The SNCA gene encoding a presynaptic protein product is thought to play a role in PD-related important pathways. It is suggested that there is a relationship between the risk of PD development and SNCA levels, and it is suggested that SNCA level is an important marker in PD diagnosis. Various polymorphisms have been identified in the 5′ and/or 3′ UTR regions of the SNCA gene, and as a result of these polymorphisms, changes occur in the binding of transcription factors. The identification of the roles of SNCA gene polymorphisms in PD development may enable the development of new methods for the treatment of PD.